Nasdaq Welcomes argenx (Nasdaq: ARGX) to The Nasdaq Stock Market

NEW YORK, May 18, 2017 -- argenx (Nasdaq:ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. 

argenx (Nasdaq:ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, visits the Nasdaq MarketSite in Times Square, in celebration of its initial public offering (IPO).

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/5b098cb8-6dcf-4f30-b37d-2d4a7b0176a9

“We are delighted to have completed our successful US IPO which will support the growth of our business, particularly as we advance our lead clinical programs ARGX-113 for severe autoimmune disease and ARGX-110 for hematological malignancies through key phase 2 trials and forward,” said Tim Van Hauwermeiren, CEO of argenx. “Establishing US trading for our stock is another element in our strategy to access the world’s most significant pharmaceutical market and other important stakeholders as we work to bring our novel products to the patients who need them.”

Based in Breda, the Netherlands, argenx is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Together with its antibody discovery and development expertise, argenx employs a suite of technologies to optimize antibodies for the discovery and development of the company’s product candidates.

“As the leading exchange for many successful health care companies, we are proud to be the listing partner of argenx as they continue to drive forward the development of antibody engineering to treat patients with cancer and severe autoimmune diseases,” said Nelson Griggs, Executive Vice President, Head of Global Listings, Nasdaq.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq.  Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 89 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com.

- NDAQG -

Media Relations Contacts:
Stephanie Lowenthal 
(646) 441-5073
[email protected]

Emily Pan
(646) 441-5120
[email protected]